Eli Lilly Reduces Zepbound Prices as Wall Street Assesses Impact on Growth
New York — Eli Lilly has lowered the price of its obesity drug Zepbound on the company’s LillyDirect platform, a move analysts say could widen patient access and support long-term earnings despite a near-term hit to revenue per prescription. The pharmaceutical firm on Monday cut the monthly cost of a starter dose of Zepbound to […]